微质密度及其与1型麻醉症患者的疾病持续时间,严重程度和素水平的关联

Lucie Barateau¹, Anis Krache¹, Alexandre Da Costa¹+14

• ¹From the Sleep-Wake Disorders Unit (L.B., S.C., Y.D.), Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier; National Reference Centre for Orphan Diseases (L.B., Y.D.), Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Montpellier; Institute of Neurosciences of Montpellier (L.B., S.B., I.J., Y.D.), University of Montpellier, INSERM; ToNIC (A.K., A.D.C., A.-S.S., S.S., P.P.), Toulouse NeuroImaging Center, UMR 1214, INSERM, Université Paul-Sabatier, Toulouse; Pediatric Sleep Centre (M.L.), Hospital Robert-Debré; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome (M.L.), Paris; Sleep Unit of Toulouse Hospital (R.D.), National Competence Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Department of Neurology; CHRU de Tours-Université de Tours (N.A., P.V.), Inserm U1253 « Imaging and Brain » (iBrain), Inserm CIC 1415, Tours; Sleep Unit (E.E.), CHU Nîmes; Radiopharmacy Department (M.A., A.-S.S.), CHU Toulouse; Critical Care Unit (S.S.), Purpan University Hospital, Toulouse; Department of Nuclear Medicine (D.M.-G.), CHU Montpellier; PhyMedExp (D.M.-G.), University of Montpellier, INSERM, CNRS; and Nuclear Medicine Department (P.P.), CHU Toulouse, France.